GO:0004692 cGMP-dependent protein kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004692 defines the molecular function of cGMP-dependent protein kinases (PKGs), which catalyze ATP-dependent phosphorylation of protein substrates in response to cyclic GMP.
• PKG is a serine/threonine kinase that exists as type I (PKG Iα, PKG Iβ) and type II (PKG II) isoforms, each with distinct tissue distribution and substrate specificity.
• PKG activation requires binding of cGMP to regulatory domains, relieving autoinhibition and enabling phosphorylation of targets such as EGFR, IRAG, and VASP.
• Dysregulated PKG signaling is implicated in cancer, retinal degeneration, and infectious diseases, making it a therapeutic target.
• CRISPR-based knockout, point mutation, and knock-in models are essential to dissect PKG isoform-specific functions and substrate networks.
• EDITGENE provides comprehensive CRISPR services to generate PKG-related cell models for mechanistic and drug discovery studies.
Description
cGMP-dependent protein kinase activity (GO:0004692) is a molecular function that enables the phosphorylation of protein substrates using ATP as a phosphate donor, specifically triggered by the second messenger cyclic GMP (cGMP). This activity is mediated by the PKG family of serine/threonine kinases, which are central effectors of nitric oxide (NO) and natriuretic peptide signaling pathways. The enzyme's ability to translate cGMP signals into phosphorylation events makes it a critical regulator of smooth muscle relaxation, platelet aggregation, and neuronal plasticity. Researchers study GO:0004692 to understand how cGMP signaling controls physiological processes and how its dysregulation contributes to diseases such as cancer, retinal degeneration, and malaria. The kinase activity is highly conserved across species, from mammals to plants and protozoan parasites, underscoring its fundamental importance. In this article, we provide a comprehensive overview of the mechanism, key genes, disease relevance, and research methods for studying cGMP-dependent protein kinase activity.
cGMP-dependent protein kinase activity At A Glance
| GO ID | GO:0004692 |
|---|---|
| GO term | cGMP-dependent protein kinase activity |
| Ontology | molecular_function |
| Synonym | PKG, PKG 1alpha, PKG 1beta, PKG II, STK23, 3':5'-cyclic GMP-dependent protein kinase activity |
| Major function | Phosphorylation of protein substrates in response to cGMP signaling |
| Reaction | ATP + a protein = ADP + a phosphoprotein |
| Cofactor | cGMP (allosteric activator) |
| Substrates | EGFR, IRAG, VASP, and other serine/threonine residues |
| Isoforms | PKG Iα, PKG Iβ, PKG II |
What Is GO:0004692?
According to the Gene Ontology, cGMP-dependent protein kinase activity (GO:0004692) is defined as the cGMP-dependent catalysis of the reaction: ATP + a protein = ADP + a phosphoprotein. In other words, it is the enzymatic activity of a kinase that transfers a phosphate group from ATP to a protein substrate, but only when activated by the binding of cyclic GMP. This activity is characteristic of the PKG family of enzymes, which are also known as cGMP-dependent protein kinases.
Why Is cGMP-dependent protein kinase activity Important in Cell Biology?
cGMP-dependent protein kinase activity is a cornerstone of signal transduction pathways that regulate cardiovascular, neuronal, and immune functions. Its ability to phosphorylate diverse substrates allows it to control smooth muscle tone, platelet activation, and gene expression. Dysregulation of this activity is linked to hypertension, cancer, and retinal degeneration, making it a prime target for therapeutic intervention. Understanding GO:0004692 is therefore essential for both basic biology and translational research.
• Regulates smooth muscle relaxation and blood pressure.
• Inhibits platelet aggregation and thrombosis.
• Modulates cancer cell proliferation and invasion, e.g., in melanoma.
• Protects against retinal degeneration in models like rd10 mice.
• Plays a role in infectious diseases, such as malaria.
• Involved in plant gibberellin signaling and salt stress responses.
• Serves as a target for drugs like sildenafil and riociguat.
• Essential for learning and memory processes in the brain.
• Provides a paradigm for allosteric kinase regulation.
• Enables cross-species studies due to evolutionary conservation.
Mechanism, Genes and Research Methods
cGMP Binding and Allosteric Activation
In simple terms: cGMP binds to the kinase and switches it on.
In the absence of cGMP, PKG is autoinhibited by its regulatory domain. Binding of cGMP to the regulatory domain induces a conformational change that relieves autoinhibition, allowing the catalytic domain to phosphorylate substrates. This allosteric activation is a key feature of GO:0004692 and has been studied in detail in Plasmodium falciparum PKG.
Substrate Recognition and Phosphorylation
In simple terms: The active kinase adds phosphate groups to specific proteins.
Activated PKG recognizes substrates with consensus sequences, often containing basic residues near the phosphorylation site. It transfers the gamma-phosphate of ATP to serine or threonine residues on target proteins, such as EGFR at threonine 669 and IRAG. This phosphorylation modulates substrate activity, leading to downstream cellular responses.
Isoform-Specific Functions
In simple terms: Different PKG types do different jobs in cells.
PKG Iα and Iβ are soluble enzymes with distinct N-terminal sequences that affect subcellular localization and substrate specificity. PKG II is membrane-associated and has a unique role in intestinal secretion and bone growth. These isoforms are encoded by different genes (PRKG1 and PRKG2) and are differentially expressed across tissues.
Regulation by Phosphodiesterases and cGMP Levels
In simple terms: The amount of cGMP controls how active the kinase is.
Intracellular cGMP levels are tightly regulated by guanylyl cyclases and phosphodiesterases (PDEs). PDE5 inhibitors, such as sildenafil, increase cGMP and thereby enhance PKG activity. This regulation is critical for physiological responses like vasodilation and is exploited pharmacologically.
Structural Determinants of Kinase Activity
In simple terms: The shape of the kinase determines how it works.
PKG is a homodimer with each monomer comprising a regulatory domain, a catalytic domain, and a dimerization domain. Crystal structures have revealed the molecular basis for cGMP binding and allosteric inhibition, as shown for the Plasmodium PKG. These structural insights guide the design of selective inhibitors and activators.
Key Genes Involved in GO:0004692 cGMP-dependent protein kinase activity
The following genes encode proteins that either possess cGMP-dependent protein kinase activity or are key substrates and regulators of this activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRKG1 | Encodes PKG Iα and Iβ isoforms | Major effector of NO/cGMP signaling; implicated in cardiovascular disease and cancer |
| PRKG2 | Encodes PKG II | Regulates intestinal secretion, bone growth, and nociception |
| EGFR | Substrate of PKG II; phosphorylated at T669 | PKG-mediated phosphorylation inhibits EGFR activation, affecting cancer cell proliferation |
| IRAG | Inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate | Mediates PKG effects on calcium signaling and smooth muscle relaxation |
| VASP | Vasodilator-stimulated phosphoprotein | Phosphorylated by PKG, regulates actin dynamics and platelet function |
| MYPT1 | Myosin phosphatase target subunit 1 | Phosphorylated by PKG, leading to smooth muscle relaxation |
| RGS2 | Regulator of G protein signaling 2 | Phosphorylated by PKG, modulates G protein-coupled receptor signaling |
| TSC2 | Tuberous sclerosis complex 2 | Phosphorylated by PKG, linking cGMP to mTOR inhibition |
| LASP1 | LIM and SH3 protein 1 | Substrate of PKG in platelets and cancer cells |
| GUCY1A3 | Guanylyl cyclase subunit alpha-1 | Produces cGMP, upstream activator of PKG |
| GUCY1B3 | Guanylyl cyclase subunit beta-1 | Produces cGMP, upstream activator of PKG |
| PDE5A | cGMP-specific phosphodiesterase | Degrades cGMP, thereby regulating PKG activity |
| PDE9A | High-affinity cGMP-specific phosphodiesterase | Regulates cGMP levels in brain and other tissues |
| PRKAR1A | cAMP-dependent protein kinase type I regulatory subunit | Cross-talk with PKG signaling |
| PRKACA | cAMP-dependent protein kinase catalytic subunit | Cross-talk with PKG signaling |
| STK23 | Serine/threonine kinase 23 (synonym for PKG I) | Alternative name for PRKG1 |
| PfPKG | Plasmodium falciparum cGMP-dependent protein kinase | Essential for malaria parasite life cycle; target for antimalarials |
| AtPKG | Arabidopsis thaliana cGMP-dependent protein kinase | Role in gibberellin signaling and salt stress |
How Is cGMP-dependent protein kinase activity Regulated?
cGMP-dependent protein kinase activity is regulated at multiple levels. Intracellular cGMP concentrations are controlled by the balance between synthesis by guanylyl cyclases and degradation by phosphodiesterases (PDEs). Allosteric activation by cGMP binding is the primary switch, but additional regulation occurs through phosphorylation by other kinases, subcellular localization, and interaction with regulatory proteins. For example, PKG II is membrane-targeted via myristoylation, which affects its substrate access. Cross-talk with cAMP-dependent protein kinase (PKA) pathways also modulates PKG activity. In disease contexts, altered expression of PKG isoforms and mutations in PRKG1 have been observed.
cGMP-dependent protein kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRKG1 | Hypertension, cancer, platelet disorders | Knockout mice, point-mutation cell lines |
| PRKG2 | Intestinal secretion disorders, bone growth defects | Knock-in mice, organoids |
| EGFR | Cancer (melanoma, lung cancer) | Overexpression and point-mutation cell lines |
| PDE6 | Retinal degeneration (retinitis pigmentosa) | rd10 mouse model, iPSC-derived photoreceptors |
| PfPKG | Malaria | Parasite knockout, biochemical assays |
Cancer
cGMP-dependent protein kinase activity can suppress tumor growth and invasion. In melanoma, activation of PKG restricts proliferation and invasion by interfering with the EGF/EGFR pathway. PKG II phosphorylates EGFR at threonine 669, inhibiting its activation and downstream signaling. Loss of PKG expression or activity is associated with poor prognosis in several cancers, making it a potential therapeutic target.
Retinal Degeneration
In retinal degeneration, cGMP levels rise due to mutations in PDE6, leading to excessive PKG activity that contributes to photoreceptor cell death. Studies in rd10 mice show altered kinase activity profiles and phosphoproteomics during cGMP-dependent retinal degeneration. Inhibiting PKG has been proposed as a neuroprotective strategy.
Infectious Diseases
The cGMP-dependent protein kinase of Plasmodium falciparum (PfPKG) is essential for the parasite's life cycle, including egress from host cells and invasion. Its unique allosteric inhibition mechanism has been characterized, and specific inhibitors are being developed as antimalarials. Thus, GO:0004692 is directly relevant to malaria pathogenesis.
Cardiovascular and Metabolic Disorders
PKG I mediates smooth muscle relaxation and platelet inhibition, and its dysfunction is linked to hypertension and thrombosis. PKG II regulates intestinal fluid secretion and bone growth, with implications for cystic fibrosis and osteoporosis. Modulators of cGMP signaling, such as PDE5 inhibitors, are used clinically for erectile dysfunction and pulmonary hypertension.
From cGMP-dependent protein kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PRKG1 knockout affect smooth muscle relaxation? | PRKG1 knockout mouse or CRISPR KO cell line |
| How does PKG II phosphorylation of EGFR T669 affect cancer growth? | Point mutation (T669A) knock-in in cancer cells |
| What is the role of PKG Iα vs Iβ in platelets? | Isoform-specific knockout or tagged knock-in |
| Can PKG activation rescue retinal degeneration? | rd10 mouse with PKG overexpression or knockout |
| What are the substrates of PfPKG? | Parasite PKG knockout and phosphoproteomics |
| How does cGMP binding allosterically activate PKG? | Recombinant PKG with point mutations in cGMP-binding domain |
How to Study the cGMP-dependent protein kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinase activity assay | Phosphorylation of substrate | Determining PKG specific activity and inhibitor efficacy |
| Phosphoproteomics | Global phosphorylation changes | Mapping PKG substrate networks in cells |
| FRET reporters | Real-time PKG activity | Live-cell imaging of cGMP dynamics |
| CRISPR knockout screening | Gene essentiality and modifiers | Identifying synthetic lethal partners of PKG |
| Western blotting | Phosphorylation of specific substrates | Validating PKG targets like EGFR T669 |
| Immunoprecipitation | Protein-protein interactions | Isolating PKG complexes |
| Structural biology (crystallography/cryo-EM) | 3D structure of PKG | Understanding allosteric regulation |
| RNA-seq | Transcriptional changes | Assessing downstream effects of PKG activation |
Kinase Activity Assays
In vitro kinase assays using recombinant PKG and substrate peptides measure the transfer of radiolabeled phosphate from ATP to substrate. These assays are used to determine specific activity, IC50 for inhibitors, and the effect of mutations. They are fundamental for studying GO:0004692.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics identifies global changes in protein phosphorylation upon PKG activation or inhibition. This approach has been used to map PKG substrates in melanoma and retinal degeneration models. It provides unbiased insights into signaling networks downstream of cGMP.
Genetically Encoded Reporters
FRET-based cGMP and PKG activity reporters allow real-time monitoring of kinase activity in live cells. These reporters have been used to study compartmentalized cGMP signaling and PKG dynamics. They enable spatial and temporal resolution of GO:0004692 in physiological contexts.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate PKG activity or sensitivity to PKG modulators. Such screens have been applied to discover synthetic lethal interactions with PKG in cancer. They are powerful for uncovering novel regulators of cGMP signaling.
How CRISPR Can Be Used to Study GO:0004692 cGMP-dependent protein kinase activity
Knockout
CRISPR knockout of PRKG1 or PRKG2 eliminates PKG isoform expression, allowing researchers to study loss-of-function phenotypes in cell models. For example, PRKG1 knockout in melanoma cells can test whether PKG activity is required for EGFR inhibition. Knockout models are also used to validate drug targets and identify compensatory pathways.
Point Mutation
Point mutations can be introduced into the catalytic or regulatory domains of PKG to dissect specific residues involved in cGMP binding, ATP hydrolysis, or substrate recognition. For instance, mutating the cGMP-binding site can create a constitutively inactive or active kinase. Such models help distinguish between kinase-dependent and independent functions.
Knock-in
Knock-in of tagged PKG (e.g., GFP or HA) enables visualization and affinity purification of the kinase in its native context. Knock-in of disease-associated mutations, such as those found in PRKG1, can model human disorders. These models are valuable for studying PKG localization and interactome.
Overexpression
Overexpression of wild-type or mutant PKG in cell lines can amplify signaling and reveal downstream effects. For example, overexpressing PKG II in cancer cells inhibits EGFR activation and proliferation. Overexpression models are also used for drug screening to identify PKG activators or inhibitors.
How EDITGENE Supports cGMP-dependent protein kinase activity Research
Researchers studying cGMP-dependent protein kinase activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway or disease phenotype. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation of PKG isoforms, substrates, and regulators.
Contact EDITGENE today to design your custom CRISPR model for cGMP-dependent protein kinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PRKG1 Knockout HEK293 Cell Line | EDJ-KQ1841 | Human | 5592 | Details Get a Quote |
| PRKG2 Knockout HEK293 Cell Line | EDJ-KQ1842 | Human | 5593 | Details Get a Quote |
| PRKG2 Knockout HeLa Cell Line | EDJ-KQ20388 | Human | 5593 | Details Get a Quote |
| PRKG2 Knockout A-549 Cell Line | EDJ-KQ21697 | Human | 5593 | Details Get a Quote |
| PRKG2 Knockout HCT 116 Cell Line | EDJ-KQ21698 | Human | 5593 | Details Get a Quote |
| PRKG1 Knockout HeLa Cell Line | EDJ-KQ54214 | Human | 5592 | Details Get a Quote |
| PRKG1 Knockout A-549 Cell Line | EDJ-KQ62707 | Human | 5592 | Details Get a Quote |
| PRKG1 Knockout HCT 116 Cell Line | EDJ-KQ71179 | Human | 5592 | Details Get a Quote |
Frequently Asked Questions About cGMP-dependent protein kinase activity
What is cGMP-dependent protein kinase activity?
It is the enzymatic activity (GO:0004692) of PKG enzymes that phosphorylate protein substrates in response to cyclic GMP, as defined by the Gene Ontology.
What genes are involved in cGMP-dependent protein kinase activity?
The main genes are PRKG1 (encoding PKG Iα and Iβ) and PRKG2 (encoding PKG II). Substrates include EGFR, IRAG, and VASP.
How is cGMP-dependent protein kinase activity regulated?
It is regulated by intracellular cGMP levels, which are controlled by guanylyl cyclases and phosphodiesterases. Allosteric binding of cGMP activates the kinase.
What diseases are associated with cGMP-dependent protein kinase activity?
Dysregulation is linked to cancer, retinal degeneration, cardiovascular disorders, and malaria.
What is the difference between PKG I and PKG II?
PKG I (α and β) are soluble and widely expressed, while PKG II is membrane-associated and found in intestine, bone, and brain. They are encoded by different genes.
How can I study cGMP-dependent protein kinase activity in the lab?
Common methods include kinase activity assays, phosphoproteomics, FRET reporters, and CRISPR knockout models.
What are the substrates of cGMP-dependent protein kinase?
Known substrates include EGFR (T669), IRAG, VASP, MYPT1, and RGS2, among others.
Can CRISPR be used to study cGMP-dependent protein kinase activity?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect PKG function and substrate networks.
What is the role of cGMP-dependent protein kinase in cancer?
PKG activation can inhibit cancer cell proliferation and invasion, for example by phosphorylating EGFR and interfering with EGF signaling.
How does cGMP-dependent protein kinase contribute to retinal degeneration?
Excessive PKG activity due to high cGMP levels can lead to photoreceptor death. Inhibiting PKG is being explored as a therapy.
Conclusion
cGMP-dependent protein kinase activity (GO:0004692) is a fundamental molecular function that translates cGMP signals into phosphorylation events, controlling diverse physiological processes. Its dysregulation is implicated in cancer, retinal degeneration, and infectious diseases, making it a key research and therapeutic target. Advanced CRISPR models and multi-omics approaches are essential to fully understand its mechanisms and to develop targeted interventions. EDITGENE's comprehensive services empower researchers to accelerate discoveries in this field.
References
- 1. Butt E. 2009. cGMP-dependent protein kinase modulators.. Handb Exp Pharmacol PMID: 19089338
- 2. Quadri M et al.. 2022. Activation of cGMP-Dependent Protein Kinase Restricts Melanoma Growth and Invasion by Interfering with the EGF/EGFR Pathway.. J Invest Dermatol 142(1):201-211 PMID: 34265328
- 3. Roy A et al.. 2024. Integrative Kinase Activity Profiling and Phosphoproteomics of rd10 Mouse Retina during cGMP-Dependent Retinal Degeneration.. Int J Mol Sci 25(6) PMID: 38542418
- 4. Lan T et al.. 2019. Type II cGMP-dependent protein kinase phosphorylates EGFR at threonine 669 and thereby inhibits its activation.. Biochem Biophys Res Commun 518(1):14-18 PMID: 31395339
- 5. Lorenz R et al.. 2017. cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase as Cyclic Nucleotide Effectors.. Handb Exp Pharmacol 238:105-122 PMID: 27885524
- 6. Byun JA et al.. 2020. Mechanism of allosteric inhibition in the Plasmodium falciparum cGMP-dependent protein kinase.. J Biol Chem 295(25):8480-8491 PMID: 32317283
- 7. Shen Q et al.. 2019. Dual Activities of Plant cGMP-Dependent Protein Kinase and Its Roles in Gibberellin Signaling and Salt Stress.. Plant Cell 31(12):3073-3091 PMID: 31575723
- 8. Feil R et al.. 1993. Expression of cGMP-dependent protein kinase in Escherichia coli.. Mol Cell Biochem 127-128:71-80 PMID: 7935364
